HUTCHMED (China) Ltd
HCM
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
Near-term hurdles, long-term upside.
stocks
Undervalued ASX share upgrades guidance
Market share gains drive earnings upgrade despite a weak US housing backdrop.
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,097.70 | 65.40 | 0.72% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,210.08 | 262.83 | 0.51% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,214.67 | 7.49 | 0.03% |
| NASDAQ | 24,932.08 | 43.74 | -0.18% |
| Nikkei 225 | 62,338.60 | 2,592.59 | -3.99% |
| NZX 50 Index | 13,861.93 | 11.24 | 0.08% |
| S&P 500 | 7,413.18 | 1.20 | 0.02% |
| S&P/ASX 200 | 8,933.10 | 70.90 | 0.80% |
| SSE Composite Index | 3,815.42 | 42.82 | -1.11% |